Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3553) 3553
Publication (295) 295
Book Review (42) 42
Book Chapter (23) 23
Dissertation (12) 12
Magazine Article (12) 12
Conference Proceeding (7) 7
Data Set (2) 2
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ezetimibe (3209) 3209
humans (2127) 2127
index medicus (1605) 1605
male (1185) 1185
female (1025) 1025
anticholesteremic agents - therapeutic use (1007) 1007
cholesterol (950) 950
azetidines - therapeutic use (884) 884
statins (850) 850
middle aged (848) 848
simvastatin (795) 795
cholesterol, ldl - blood (712) 712
drug therapy, combination (711) 711
cardiac & cardiovascular systems (655) 655
aged (645) 645
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (608) 608
hypercholesterolemia - drug therapy (605) 605
pharmacology & pharmacy (596) 596
hypercholesterolemia (592) 592
treatment outcome (519) 519
atorvastatin (513) 513
atherosclerosis (469) 469
lipids (456) 456
anticholesteremic agents - administration & dosage (441) 441
animals (435) 435
adult (431) 431
efficacy (420) 420
azetidines - administration & dosage (413) 413
safety (400) 400
risk factors (397) 397
azetidines - pharmacology (375) 375
simvastatin - therapeutic use (362) 362
low density lipoproteins (358) 358
anticholesteremic agents - pharmacology (347) 347
medicine, general & internal (344) 344
coronary-heart-disease (340) 340
peripheral vascular disease (330) 330
statin therapy (324) 324
cardiovascular (323) 323
statin (300) 300
risk (297) 297
anticholesteremic agents - adverse effects (293) 293
cardiovascular disease (277) 277
therapy (271) 271
hypercholesterolemia - blood (259) 259
azetidines - adverse effects (257) 257
abridged index medicus (256) 256
cholesterol - metabolism (256) 256
double-blind method (249) 249
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (244) 244
ezetimibe - therapeutic use (241) 241
antilipemic agents (240) 240
cholesterol - blood (239) 239
density-lipoprotein cholesterol (234) 234
primary hypercholesterolemia (234) 234
cardiovascular diseases - prevention & control (233) 233
biochemistry & molecular biology (231) 231
prevention (229) 229
simvastatin - administration & dosage (221) 221
analysis (220) 220
care and treatment (216) 216
drug therapy (212) 212
mice (212) 212
dyslipidemia (211) 211
research (211) 211
disease (210) 210
rosuvastatin (209) 209
cholesterol absorption (207) 207
hypolipidemic agents - therapeutic use (205) 205
dyslipidemias - drug therapy (204) 204
drug combinations (201) 201
coronary heart disease (198) 198
metabolism (195) 195
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (194) 194
ldl cholesterol (191) 191
cholesterol absorption inhibitor (187) 187
cardiovascular-disease (185) 185
familial hypercholesterolemia (179) 179
cardiovascular diseases (178) 178
triglycerides - blood (174) 174
endocrinology & metabolism (173) 173
double-blind (170) 170
atorvastatin calcium (169) 169
cholesterol, hdl - blood (165) 165
aged, 80 and over (164) 164
lipoproteins (163) 163
cholesterol, ldl - drug effects (162) 162
absorption (157) 157
medicine & public health (157) 157
cardiology (155) 155
c-reactive protein (154) 154
hyperlipidemias - drug therapy (154) 154
metaanalysis (154) 154
triglycerides (153) 153
time factors (151) 151
dose-response relationship, drug (150) 150
lipids - blood (148) 148
intestinal absorption - drug effects (146) 146
randomized controlled trials as topic (142) 142
cardiovascular agents (140) 140
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3228) 3228
German (81) 81
Spanish (71) 71
French (42) 42
Czech (31) 31
Russian (30) 30
Hungarian (25) 25
Japanese (25) 25
Korean (12) 12
Italian (11) 11
Chinese (9) 9
Polish (7) 7
Portuguese (7) 7
Danish (6) 6
Turkish (4) 4
Dutch (2) 2
Finnish (2) 2
Swedish (2) 2
Hebrew (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Persian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Improved Aqueous Solubility and Antihypercholesterolemic Activity of Ezetimibe on Formulating with Hydroxypropyl-β-Cyclodextrin and Hydrophilic Auxiliary Substances
by Srivalli, Kale Mohana Raghava and Srivalli, Kale Mohana Raghava and Mishra, Brahmeshwar and Mishra, Brahmeshwar
AAPS PharmSciTech, ISSN 1530-9932, 4/2016, Volume 17, Issue 2, pp. 272 - 283
The purpose of this study was to improve the aqueous solubility, dissolution, and pharmacodynamic properties of a BCS class II drug, ezetimibe (Eze) by... 
Biochemistry, general | ezetimibe–HPBCD | Biotechnology | Biomedicine | ezetimibe–HPBCD–AA2G | Pharmacy | dissolution | Pharmacology/Toxicology | ezetimibe–HPBCD–TPGS | phase solubility | POLYMERS | ezetimibe-HPBCD-TPGS | ACID | DRUG-DELIVERY | STABILITY | ezetimibe-HPBCD-AA2G | BINARY | SOLID-STATE | ezetimibe-HPBCD | SYSTEMS | PHARMACOLOGY & PHARMACY | INCLUSION COMPLEX | 2-Hydroxypropyl-beta-cyclodextrin | Chemistry, Pharmaceutical - methods | Magnetic Resonance Spectroscopy - methods | Freeze Drying - methods | Calorimetry, Differential Scanning - methods | Pharmaceutical Solutions - chemistry | Solubility | Hypoglycemic Agents - chemistry | Ezetimibe - chemistry | Microscopy, Electron, Scanning - methods | beta-Cyclodextrins - chemistry | Excipients - chemistry | Cyclodextrins - chemistry | Water - chemistry | Ascorbic Acid - chemistry | Hydrophobic and Hydrophilic Interactions | Spectroscopy, Fourier Transform Infrared - methods | X-Ray Diffraction - methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Beneft of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients with Versus Without Diabetes Mellitus Results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Effcacy International Trial)
by Giugliano, Robert P and Cannon, Christopher P and Blazing, Michael A and Nicolau, José C and Corbalán, Ramón and Pinar, Jindrich and Park, Jeong-Gun and White, Jennifer A and Bohula, Erin A and Braunwald, Eugene
Circulation, ISSN 0009-7322, 04/2018, Volume 137, Issue 15, pp. 1571 - 1582
lipids | diabetes mellitus | ezetimibe | acute coronary syndromes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: The ODYSSEY COMBO II randomized controlled trial
by Cannon, Christopher P and Cariou, Bertrand and Blom, Dirk and McKenney, James M and Lorenzato, Christelle and Pordy, Robert and Chaudhari, Umesh and Colhoun, Helen M and ODYSSEY COMBO II Investigators
European Heart Journal, ISSN 0195-668X, 05/2015, Volume 36, Issue 19, pp. 1186 - 1194
Aims To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of alirocumab, a fully human monoclonal antibody to proprotein... 
Alirocumab | Monoclonal antibody | Low-Density Lipoprotein Cholesterol | Ezetimibe | DESIGN | CARDIAC & CARDIOVASCULAR SYSTEMS | MONOTHERAPY | CHOLESTEROL | RATIONALE | PCSK9 | MONOCLONAL-ANTIBODY | ATORVASTATIN | OUTCOMES | EVOLOCUMAB | Double-Blind Method | Drug Administration Schedule | Ezetimibe - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Treatment Outcome | Ezetimibe - administration & dosage | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Injections, Subcutaneous | Cholesterol, LDL - metabolism | Female | Track Clinical Paper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Effect of hydroxypropylcellulose and Tween 80 on physicochemical properties and bioavailability of ezetimibe-loaded solid dispersion
by Rashid, Rehmana and Kim, Dong Wuk and Kim, Jong Oh and Din, Fakhar ud and Mustapha, Omer and Yousaf, Abid Mehmood and Park, Jong Hyuck and Yong, Chul Soon and Choi, Han-Gon
Carbohydrate Polymers, ISSN 0144-8617, 10/2015, Volume 130, pp. 26 - 31
The purpose of this research was to evaluate the effect of the HPC (hydroxypropylcellulose) and Tween 80 on the physicochemical properties and oral... 
Solid dispersion | Bioavailability | Tween 80 | Ezetimibe | Solubility | Hydroxypropylcellulose | SYSTEM | POLYMER SCIENCE | WATER-SOLUBLE DRUG | BINARY | CHEMISTRY, ORGANIC | RELEASE | DELIVERY | ENHANCED SOLUBILITY | ORAL BIOAVAILABILITY | DISSOLUTION PROPERTIES | CHEMISTRY, APPLIED | IN-VIVO EVALUATION | CELLULOSE | Polysorbates - chemistry | Administration, Oral | Biological Availability | Male | Ezetimibe - administration & dosage | Rats, Sprague-Dawley | Drug Carriers - chemistry | Cellulose - chemistry | Animals | Ezetimibe - chemistry | Ezetimibe - pharmacokinetics | Surface-Active Agents - chemistry | Cellulose - analogs & derivatives | Surface active agents | Pharmacy | Antilipemic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial
by Nissen, Steven E and Stroes, Erik and Dent-Acosta, Ricardo E and Rosenson, Robert S and Lehman, Sam J and Sattar, Naveed and Preiss, David and Bruckert, Eric and Ceška, Richard and Lepor, Norman and Ballantyne, Christie M and Gouni-Berthold, Ioanna and Elliott, Mary and Brennan, Danielle M and Wasserman, Scott M and Somaratne, Ransi and Scott, Rob and Stein, Evan A and GAUSS-3 Investigators and for the GAUSS-3 Investigators
JAMA, ISSN 0098-7484, 04/2016, Volume 315, Issue 15, pp. 1580 - 1590
IMPORTANCE: Muscle-related statin intolerance is reported by 5% to 20% of patients. OBJECTIVE: To identify patients with muscle symptoms confirmed by statin... 
MEDICINE, GENERAL & INTERNAL | ALIROCUMAB | CHOLESTEROL | SAFETY | PCSK9 | MONOCLONAL-ANTIBODY | COMBINATION | Myalgia - blood | Myalgia - chemically induced | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Myositis - chemically induced | Hypercholesterolemia - drug therapy | Myositis - prevention & control | Time Factors | Adult | Cholesterol, LDL - blood | Female | Muscular Diseases - prevention & control | Ezetimibe - therapeutic use | Muscular Diseases - chemically induced | Atorvastatin Calcium - adverse effects | Hypercholesterolemia - blood | Myalgia - prevention & control | Creatine Kinase - blood | Double-Blind Method | Ezetimibe - adverse effects | Biomarkers - blood | Myositis - blood | Anticholesteremic Agents - adverse effects | Muscular Diseases - blood | Rhabdomyolysis - prevention & control | Cross-Over Studies | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Rhabdomyolysis - chemically induced | Rhabdomyolysis - blood | Clinical trials | Cholesterol, LDL | Usage | Care and treatment | Side effects | Muscular system | Comparative analysis | Drug therapy | Low density lipoprotein | Statins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
by Kazi, Dhruv S and Moran, Andrew E and Coxson, Pamela G and Penko, Joanne and Ollendorf, Daniel A and Pearson, Steven D and Tice, Jeffrey A and Guzman, David and Bibbins-Domingo, Kirsten
JAMA, ISSN 0098-7484, 08/2016, Volume 316, Issue 7, pp. 743 - 753
IMPORTANCE: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were recently approved for lowering low-density lipoprotein cholesterol in... 
GLOBAL BURDEN | MEDICINE, GENERAL & INTERNAL | ALIROCUMAB | EFFICACY | STATIN THERAPY | SAFETY | REDUCING LIPIDS | RISK PATIENTS | SUBTILISIN/KEXIN TYPE 9 | ISCHEMIC-HEART-DISEASE | EZETIMIBE | Drug Costs | Proprotein Convertases - antagonists & inhibitors | Ezetimibe - economics | Uncertainty | United States | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Aged, 80 and over | Adult | Cholesterol, LDL - blood | Female | Ezetimibe - therapeutic use | Hyperlipoproteinemia Type II - drug therapy | Serine Endopeptidases | Quality-Adjusted Life Years | Atherosclerosis - drug therapy | Hyperlipoproteinemia Type II - blood | Anticholesteremic Agents - economics | Anticholesteremic Agents - therapeutic use | Cost-Benefit Analysis | Aged | Antibodies, Monoclonal - economics | Proprotein Convertase 9 | Care and treatment | Hypercholesterolemia | Analysis | Anticholesteremic agents | Dosage and administration | Cardiovascular diseases | Risk factors | Medical care, Cost of | Cardiovascular disease | Inhibitor drugs | Health care expenditures | Cost analysis | Clinical outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Niemann-pick C1-like 1 (NPC1L1) inhibition and cardiovascular diseases
by Pirillo, A and Catapano, A.L and Norata, G.D
Current Medicinal Chemistry, ISSN 0929-8673, 03/2016, Volume 23, Issue 10, pp. 983 - 999
Circulating levels of cholesterol are derived from either endogenous production or intestinal absorption of dietary and biliary cholesterol. Niemann-Pick... 
Cardiovascular disease | Cholesterol absorption | LDL-C | NPC1L1 | Cholesterol | Ezetimibe | C1 LIKE-1 NPC1L1 | cardiovascular disease | LIPID-ALTERING-EFFICACY | CHEMISTRY, MEDICINAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | INTESTINAL CHOLESTEROL ABSORPTION | BETA-LACTAM DERIVATIVES | ENDOTHELIAL PROGENITOR CELLS | DENSITY-LIPOPROTEIN CHOLESTEROL | cholesterol absorption | ezetimibe | STATIN THERAPY | HIGH-RISK | REVERSE CHOLESTEROL | LOWERING LDL CHOLESTEROL | cholesterol | PHARMACOLOGY & PHARMACY | Ezetimibe - chemistry | Cardiovascular Diseases - metabolism | Membrane Proteins - antagonists & inhibitors | Simvastatin - chemistry | Cardiovascular Diseases - drug therapy | Humans | Ezetimibe - pharmacology | Simvastatin - pharmacology | Ezetimibe - chemical synthesis
Journal Article
Details down arrow
8. Full Text Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT
by Bohula, Erin A and Bohula, Erin A and Giugliano, Robert P and Giugliano, Robert P and Cannon, Christopher P and Cannon, Christopher P and Zhou, Jing and Zhou, Jing and Murphy, Sabina A and Murphy, Sabina A and White, Jennifer A and White, Jennifer A and Tershakovec, Andrew M and Blazing, Michael A and Blazing, Michael A and Braunwald, Eugene and Braunwald, Eugene
Circulation, ISSN 0009-7322, 2015, Volume 132, Issue 13, pp. 1224 - 1233
Background-Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP); addition of ezetimibe to statins further... 
acute coronary syndrome | C-reactive protein | secondary prevention | cholesterol, LDL | ezetimibe | LDL | hydroxymethylglutaryl-CoA reductase inhibitors | Cholesterol | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | RANDOMIZED-TRIALS | EFFICACY | SAFETY | RISK | ACUTE CORONARY SYNDROMES | HEART-DISEASE | STATIN THERAPY | INFLAMMATION | CLINICAL-TRIALS | PERIPHERAL VASCULAR DISEASE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Myocardial Infarction - blood | Simvastatin - therapeutic use | Humans | Middle Aged | Male | Cardiovascular Diseases - mortality | Electrocardiography | Cholesterol, LDL - blood | Female | Ezetimibe - therapeutic use | C-Reactive Protein - analysis | Drug Therapy, Combination | Cerebral Revascularization | Double-Blind Method | Comorbidity | Simvastatin - administration & dosage | Treatment Outcome | Ezetimibe - administration & dosage | Acute Coronary Syndrome - blood | Myocardial Revascularization | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Myocardial Infarction - drug therapy | Anticholesteremic Agents - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Biomarkers | Creatinine - blood | Aged | Drug Monitoring
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe European Atherosclerosis Society Consensus Panel
by Ference, Brian A and Ginsberg, Henry N and Graham, Ian and Ray, Kausik K and Packard, Chris J and Bruckert, Eric and Hegele, Robert A and Krauss, Ronald M and Raal, Frederick J and Schunkert, Heribert and Watt, Gerald F and Borén, Jan and Fazio, Sergio and Horton, Jay D and Masana, Luis and Nicholls, Stephen J and Nordestgaard, Børge G and Van De Sluis, Bart and Taskinen, Marja-Riitta and Tokgözoǧlu, Lale and Landmesser, Ulf and Laufs, Ulrich and Wiklund, Olov and Stock, Jane K and Chapman, M. John and Catapano, Alberico L
European Heart Journal, ISSN 0195-668X, 08/2017, Volume 38, Issue 32, pp. 2459 - 2472
Low-density lipoprotein | Recommendations | Atherosclerosis | Ezetimibe | Clinical trials | Cardiovascular disease | PCSK9 | Mendelian randomization | Statin | Causality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Evaluation of physicochemical properties and in vivo efficiency of atorvastatin calcium/ezetimibe solid dispersions
by Jahangiri, Azin and Barzegar-Jalali, Mohammad and Garjani, Alireza and Javadzadeh, Yousef and Hamishehkar, Hamed and Asadpour-Zeynali, Karim and Adibkia, Khosro
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 01/2016, Volume 82, pp. 21 - 30
Fixed-dose combination of atorvastatin calcium (ATV) and ezetimibe (EZT) provides a considerable advantage in the management of hyperlipidemia. However, both... 
Atorvastatin | Solid dispersion | In vivo evaluation | Ezetimibe | Liver steatosis | WATER-SOLUBLE DRUG | CHOLESTEROL | FATTY LIVER-DISEASE | DISSOLUTION RATE ENHANCEMENT | INCLUSION COMPLEXES | SOLVENT EVAPORATION | BIOAVAILABILITY | SOLUBILITY | POLYETHYLENE-GLYCOL 6000 | PHARMACOLOGY & PHARMACY | Liver - pathology | Hyperlipidemias - blood | Rats, Wistar | Atorvastatin Calcium - pharmacology | Fatty Liver - blood | Fatty Liver - pathology | Atorvastatin Calcium - administration & dosage | Cholesterol - blood | Hyperlipidemias - drug therapy | Atorvastatin Calcium - chemistry | Ezetimibe - pharmacology | Solubility | Male | Ezetimibe - administration & dosage | Fatty Liver - drug therapy | Povidone - chemistry | Animals | Ezetimibe - chemistry | Liver - drug effects | Diet, High-Fat | Hyperlipidemias - pathology | Ezetimibe - therapeutic use | Atorvastatin Calcium - therapeutic use | Drug Combinations | Low density lipoproteins | Analysis | Liver | Antilipemic agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia
by Bove, Marilisa and Fogacci, Federica and Cicero, Arrigo F. G
Expert Opinion on Drug Metabolism & Toxicology, ISSN 1742-5255, 10/2017, Volume 13, Issue 10, pp. 1099 - 1104
Introduction: Cholesterol lowering treatment is mainly based on statins eventually associated to adjunctive drugs of different class such as ezetimibe. In the... 
Ezetimibe/simvastatin administration | pharmacokinetics | safety | efficacy | Cardiovascular Diseases - etiology | Cardiovascular Diseases - prevention & control | Humans | Risk Factors | Ezetimibe, Simvastatin Drug Combination - administration & dosage | Half-Life | Ezetimibe, Simvastatin Drug Combination - adverse effects | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Anticholesteremic Agents - pharmacokinetics | Anticholesteremic Agents - administration & dosage | Cholesterol, LDL - blood | Hypercholesterolemia - complications | Ezetimibe, Simvastatin Drug Combination - pharmacokinetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
by Farnier, Michel and Jones, Peter and Severance, Randall and Averna, Maurizio and Steinhagen-Thiessen, Elisabeth and Colhoun, Helen M and Du, Yunling and Hanotin, Corinne and Donahue, Stephen
Atherosclerosis, ISSN 0021-9150, 2015, Volume 244, pp. 138 - 146
Abstract Objective To compare lipid-lowering efficacy of adding alirocumab to rosuvastatin versus other treatment strategies (NCT01730053). Methods Patients... 
Cardiovascular | PCSK9 | Rosuvastatin | Alirocumab | Monoclonal antibody | Low-density lipoprotein cholesterol | Ezetimibe | LDL-CHOLESTEROL | CARDIAC & CARDIOVASCULAR SYSTEMS | SUBTILISIN/KEXIN TYPE 9 | MONOCLONAL-ANTIBODY | INHIBITOR ALIROCUMAB | ATORVASTATIN | DENSITY-LIPOPROTEIN CHOLESTEROL | STATIN THERAPY | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | PERIPHERAL VASCULAR DISEASE | SERINE-PROTEASE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hypercholesterolemia - blood | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Cholesterol, LDL - drug effects | Treatment Outcome | Ezetimibe - administration & dosage | Hypercholesterolemia - drug therapy | Rosuvastatin Calcium - administration & dosage | Dose-Response Relationship, Drug | Time Factors | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Injections, Subcutaneous | Cardiovascular Diseases - blood | Cholesterol, LDL - blood | Retrospective Studies | Drug Therapy, Combination | Cardiac patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Simultaneous determination of ezetimibe and its glucuronide metabolite in human plasma by solid phase extraction and liquid chromatography–tandem mass spectrometry
by Guo, Lin and Wang, Meng-meng and He, Min and Qiu, Fu-rong and Jiang, Jian
Journal of Chromatography B, ISSN 1570-0232, 04/2015, Volume 986-987, pp. 108 - 114
A liquid chromatography–tandem mass spectrometry method (LC-MS/MS) was developed to quantify ezetimibe (EZM) and its major glucuronide (ezetimibe glucuronide,... 
LC-MS/MS | SPE | Ezetimibe glucuronide | Ezetimibe | CHEMISTRY, ANALYTICAL | INHIBITION | QUANTIFICATION | BIOCHEMICAL RESEARCH METHODS | HUMAN SERUM | IDENTIFICATION | MS/MS | INTESTINAL CHOLESTEROL ABSORPTION | Reproducibility of Results | Glucuronides - pharmacokinetics | Humans | Azetidines - pharmacokinetics | Linear Models | Male | Azetidines - chemistry | Glucuronides - blood | Ezetimibe - blood | Ezetimibe - chemistry | Ezetimibe - pharmacokinetics | Sensitivity and Specificity | Solid Phase Extraction | Azetidines - blood | Chromatography, Liquid - methods | Tandem Mass Spectrometry - methods | Glucuronides - chemistry | Hydrolysis | Enzymes | Liquid chromatography | Metabolites | Mass spectrometry | Antilipemic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper fromthe Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
by Cuchel, Marina and Bruckert, Eric and Ginsberg, Henry N and Raal, Frederick J and Santos, Raul D and Hegele, Robert A and Kuivenhoven, Jan Albert and Nordestgaard, Børge G and Descamps, Olivier S and Steinhagen-Thiessen, Elisabeth and Tybjærg-Hansen, Anne and Watts, Gerald F and Averna, Maurizio and Boileau, Catherine and Borén, Jan and Catapano, Alberico L and Defesche, Joep C and Hovingh, G. Kees and Humphries, Steve E and Kovanen, Petri T and Masana, Luis and Pajukanta, Päivi and Parhofer, Klaus G and Ray, Kausik K and Stalenhoef, Anton F.H and Stroes, Erik and Taskinen, Marja-Riitta and Wiegman, Albert and Wiklund, Olov and Chapman, M. John
European Heart Journal, ISSN 0195-668X, 08/2014, Volume 35, Issue 32, pp. 2146 - 2157
Lomitapide | Homozygous familial hypercholesterolaemia | Ezetimibe | Genetics | Mipomersen | Diagnosis | Lipoprotein apheresis | Phenotypic heterogeneity | Statins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Low-density lipoprotein cholesterol targeting with pitavastatin 1 ezetimibe for patients with acute coronary syndrome and dyslipidaemia: The HIJ-PROPER study, a prospective, open-label, randomized trial
by Hagiwara, Nobuhisa and Kawada-Watanabe, Erisa and Koyanagi, Ryo and Arashi, Hiroyuki and Yamaguchi, Junichi and Nakao, Koichi and Tobaru, Tetsuya and Tanaka, Hiroyuki and Oka, Toshiaki and Endoh, Yasuhiro and Saito, Katsumi and Uchida, Tatsuro and Matsui, Kunihiko and Ogawa, Hiroshi
European Heart Journal, ISSN 0195-668X, 08/2017, Volume 38, Issue 29, pp. 2264 - 2275
Aims To elucidate the effects of intensive LDL-C lowering treatment with a standard dose of statin and ezetimibe in patients with dyslipidaemia and high risk... 
statin plus ezetimibe may be more | Although intensive lowering with standard pitavastatin plus ezetimibe showed no more cardiovascular benefit than standard pitavastatin monotherapy in ACS patients with dyslipidaemia | EARLY STATIN TREATMENT | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | RATIONALE | Ezetimibe | Combination therapy | FAILURE | ATORVASTATIN | Pitavastatin | HEART INSTITUTE | THERAPY | JAPAN | ACUTE MYOCARDIAL-INFARCTION | Clinical trial | Lipid-lowering | Acute coronary syndrome | ARTERY-DISEASE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe
by Soulele, Konstantina and Karalis, Vangelis
Xenobiotica, ISSN 0049-8254, 04/2019, Volume 49, Issue 4, pp. 446 - 456
Ezetimibe is a potent cholesterol absorption inhibitor, with an erratic pharmacokinetic (PK) profile, attributed to an extensive enterohepatic recirculation... 
enterohepatic recirculation | enterohepatic recirculation models | Population pharmacokinetics | ezetimibe | pharmacokinetic modeling | CIRCULATION | MECHANISM | GLUCURONIDE METABOLITE | MODEL | PARAMETERS | DISPOSITION | CHOLESTEROL ABSORPTION INHIBITOR | PRIMARY HYPERCHOLESTEROLEMIA | PHARMACOLOGY & PHARMACY | TOXICOLOGY | SCH58235 | MYCOPHENOLIC-ACID | Dose-Response Relationship, Drug | Administration, Oral | Enterohepatic Circulation - drug effects | Ezetimibe - pharmacokinetics | Humans | Ezetimibe - pharmacology | Adult | Female | Male | Ezetimibe - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
by Cannon, Christopher P and Blazing, Michael A and Giugliano, Robert P and McCagg, Amy and White, Jennifer A and Theroux, Pierre and Darius, Harald and Lewis, Basil S and Ophuis, Ton Oude and Jukema, J. Wouter and De Ferrari, Gaetano M and Ruzyllo, Witold and De Lucca, Paul and Im, KyungAh and Bohula, Erin A and Reist, Craig and Wiviott, Stephen D and Tershakovec, Andrew M and Musliner, Thomas A and Braunwald, Eugene and Califf, Robert M and IMPROVW-IT Investigators and IMPROVE-IT Investigators
The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 25, pp. 2387 - 2397
In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At... 
CHOLESTEROL ABSORPTION | CARDIAC OUTCOMES | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | EFFICACY | CARDIOVASCULAR OUTCOMES | CLINICAL-TRIALS | SIMVASTATIN | PRIMARY PREVENTION | IMPROVE-IT | ATORVASTATIN | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article